Joël Jean-Mairet, PhD
Joël is managing partner and co-founder of Ysios Capital. Previously, he co-founded Glycart Biotechnology AG in 2001 and was its CEO until the company was successfully sold to F. Hoffmann La-Roche in 2005. Joël is currently on the Boards of Aura Biosciences, Ona Therapeutics, Sanifit Therapeutics, executive chairman at Inbiomotion, and board observer at AM-Pharma. Formerly, he was board observer at Biovex (now Amgen), chairman of the board at Cellerix/TiGenix (now Takeda) and Board member of Medlumics S.L., Dermalumics S.L. He has earned numerous awards, including the Wall Street Journal Europe Innovation Award in 2001. Joël holds a master degree in Biotechnology and earned his PhD from the Swiss Federal Institute of Technology (ETH) in Zurich.